ProhostBiotech.Com

Most Discussed Stocks

AMGEN, AMGN

DENDREON,DNDN

DYAX, DYAX

ELAN, ELN

GENENTECH,DNA

REGENERON,RGEN

SEQUENOM,SQNM

EXELIXIS, EXEL

WE ARE BACK FROM HALF REST, GILEAD, TYSABRI AND OTHER STORIES

January is almost gone, and February is knocking on the door. Be ready to hear good news. We have plenty. For subscribers Only.

	SUNESIS PHARMACEUTICALS (SNSS): RESULTS CANNO....	01/02/2010
	At the 51st American Society Hematology (ASH) Annual Meeting in New Orleans, LA. Sunesis presented positive data from two Phase 2 clinical trials of its drug Voreloxin drug for acu....

	CompuGen (CGEN): Biotech firms are no dreamer....	12/23/2009
	The high-risk biotech firms are proving time after time that they are low risk. Now, following the melting of the economy story, the biotech firms can be seen as no risk compared t....

	WAS ARRAY\'S LUCRATIVE DEAL WITH AMGEN REALLY....	12/16/2009
	In November, Array hinted to a partnership, but unfortunately, many preferred to listen to the wrong voices. Fortunately, though, there is something called profit-taking.

	GERON (GERN): WE ARE REGAINING OUR ENTHUSIASM	12/08/2009
	We are optimistic. The truth is that we are in the process of regaining our enthusiasm for Geron.

	THE FDA APPROVES DYAX’ (DYAX) DRUG KALBITOR® ....	12/02/2009

	THE IMPORTANCE OF MICROMET AND CYTOKINETIC PR....	11/29/2009

	NEUROGESX (NGSX): QUTENZA THE FIRST APPROVED ....	11/17/2009
	The FDA has approved NeurogesX' drug Qutenza (capsaicin patch) for neuropathic pain due to post-herpetic neuralgia (PHN).